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a b s t r a c t
Human papillomavirus (HPV) 33, a member of the HPV16-related alpha-9 species group, is found in
approximately 5% of cervical cancers worldwide. The current study aimed to characterize the genetic
diversity of HPV33 and to explore the association of HPV33 variants with the risk for cervical cancer.
Taking advantage of the International Agency for Research on Cancer biobank, we sequenced the entire
E6 and E7 open reading frames of 213 HPV33-positive cervical samples from 30 countries. We identiﬁed
28 HPV33 variants that formed 5 phylogenetic groups: the previously identiﬁed A1, A2, and B (sub)
lineages and the novel A3 and C (sub)lineages. The A1 sublineage was strongly over-represented in
cervical cases compared to controls in both Africa and Europe. In conclusion, we provide a classiﬁcation
system for HPV33 variants based on the sequence of E6 and E7 and suggest that the association of HPV33
with cervical cancer may differ by variant (sub)lineage.
& 2013 Elsevier Inc. All rights reserved.
Background
A subset of human papillomaviruses (HPV) is considered the
necessary cause of cervical cancer and a proportion of other
anogenital and head and neck carcinomas (Bouvard et al., 2009).
While infection with a high-risk HPV is a common event among
sexually active women, the majority of infections are cleared
within 2 years (Goodman et al., 2008; Insinga et al., 2009;
Plummer et al., 2007; Rosa et al., 2008). There is a need to identify
the factors that inﬂuence a patient's progression from HPV infec-
tion to viral persistence, cellular transformation, and cervical
cancer. Current evidence suggests that sequence variations within
HPV16 and HPV18 may inﬂuence viral persistence and clinical
outcome (Gheit et al., 2011; Schiffman et al., 2010; Zuna et al.,
2009; Sathish et al., 2005; Villa et al., 2000; Berumen et al., 2001).
HPV33 is a high-risk HPV within the same phylogenetic species
(alpha-9) as HPV16 (Bernard et al., 2010; de Villiers et al., 2004)
and accounts for approximately 5% of cervical cancer cases world-
wide, with some variation in this proportion by geographical
region (Guan et al., 2012; Li et al., 2011). For example, while
HPV33 is found in 5.4% of cervical cancer cases in Eastern Asia, it is
only found in 1.7% of cases in Oceania (Li et al., 2011). HPV33 was
originally cloned from an invasive cervical carcinoma (Beaudenon
et al., 1986), and the entire viral sequence was described shortly
after (Cole and Streeck, 1986). Since then, a few studies have
described genetic variation in HPV33 worldwide (Chen et al., 2011;
Stewart et al., 1996; Godínez et al., 2013) of which the most
comprehensive was based upon the whole genome sequencing of
20 HPV33-positive samples (Chen et al., 2011). HPV33 variants
were classiﬁed into two major lineages, A and B. The A lineage was
further divided into two sublineages, A1, which includes the
prototype sequence [M12732.1 (Cole and Streeck, 1986)], and A2.
This classiﬁcation is based upon the deﬁnition that the full
genome sequence of a major variant lineage differs by approxi-
mately 1.0% from another variant lineage of the same HPV type,
with differences of 0.5–0.9% deﬁning sublineages (Chen et al.,
2011).
Previous studies of HPV33 variants and clinical outcome have
tended to be small and focused on a particular geographical region
or ethnic group (Khouadri et al., 2006; Bokal et al., 2010; Gagnon
et al., 2004; Garbuglia et al., 2007; Ntova et al., 2012; Raiol et al.,
2009; Wu et al., 2009; Xin et al., 2001). Hence, the aims of the
current study were to further characterize the genetic diversity of
HPV33 worldwide and to explore the association of well-deﬁned
HPV33 variant lineages with the risk for cervical cancer. To do this,
we sequenced and analyzed the entire E6 and E7 open reading
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frames of HPV33-positive cervical samples stored at the Interna-
tional Agency for Research on Cancer (IARC), including cervical
cancer cases and controls collected during more than 20 years of
studies on HPV.
Materials and methods
Origin of clinical specimens
The IARC has coordinated cervical cancer case series, cervical
cancer case-control studies, and population-based HPV prevalence
surveys in a large number of countries around the world (Bosch
et al., 1995; Muñoz et al., 2003; Franceschi et al., 2003; Clifford
et al., 2005; Li et al., 2006; Bardin et al., 2008; Dondog et al., 2008;
Keita et al., 2009; Sherpa et al., 2010; Alibegashvili et al., 2011; De
Vuyst et al., 2012; Aruhuri et al., 2012; Sideri et al., 2009) and as
yet unpublished studies from Fiji, Bhutan, and Senegal. The
collection of samples has spanned a period of over 20 years, but
predates the introduction of HPV vaccines. Informed consent was
obtained from all participants, and the studies were approved by
the IARC Ethical Review Committee. Cervical samples (exfoliated
cells or tissue biopsy specimens) derived from these studies have
been comprehensively genotyped for 37 HPV types by using a
standardized and well-validated protocol (General Primer GP5þ/
6þPCR–EIA followed by reverse line blot assay) (van den Brule
et al., 2002) in one centralized laboratory (Molecular Pathology
Unit, Department of Pathology, VU University Medical Center,
Amsterdam, The Netherlands). All HPV33-positive cervical sam-
ples in the IARC biobank were selected for the current analysis,
without exclusion, and were categorized into the following
regions: Africa, Asia and Oceania, Europe, and South America.
Country speciﬁc details are noted in Table 1.
PCR and DNA sequencing
DNA extraction from stored samples was performed using the
High Pure PCR Template Preparation Kit (Roche, Mannheim,
Germany), and DNA isolates were subjected to β-globin PCR to
assess sample quality, as described previously (Hesselink et al.,
2009). Sequencing of the entire HPV33 E6 and E7 region (nucleo-
tides 109–866) was performed as described previously (Godínez
et al., 2013) using a series of HPV33 speciﬁc primer pairs that were
designed to amplify overlapping regions of the HPV33 E6 and E7
open reading frames in order to cover the entire E6 and E7 region.
To reveal single nucleotide polymorphisms (SNPs), sequences
of the specimens were aligned to the prototype HPV33 sequence
(NCBI accession number M12732) using multalin software (http://
multalin.toulouse.inra.fr/ multalin/). SNPs that were observed in only
one sample were conﬁrmed by re-examination of the sequence
traces. Isolates that did not classify into existing lineage categories
were conﬁrmed by manual re-examination of the sequencing traces
and with additional sequencing, where necessary. Multiple sequence
traces for each sample were compiled to provide one sequence
encompassing the entire HPV33 E6 and E7 region. All sequences
were submitted to GenBank (accessions KC862070–KC862080,
KC881011–KC881020, and KF536962–KF536968).
Phylogenetic analysis
Unrooted consensus trees were built using the Phylogeny
Inference Package (PHYLIP), version 3.69 (Felsenstein, 1989). This
included generating 10,000 bootstraps using the F84 model of
DNA distances, clustering with the unweighted pair group method
with arithmetic mean (UPGMA), and applying the majority rule
extended, or greedy, method of consensus. Trees created with a
maximum-likelihood method showed similar results and are not
described further. For the principal tree analysis, all unique
sequence variants found in IARC samples were included. In a
subsequent analysis, IARC variants were supplemented by other
unique E6/E7 sequences reported in the literature, including 2 from
Garbuglia et al. (2007), 6 from Khouadri et al. (2006), 1 from
Wu et al. (2009), and 4 from Chen et al. (2011) and personal
communication. The IARC samples that contained a variant that
appeared to belong to a newly described (sub)lineage were full-
genome sequenced as described previously (Chen et al., 2011) to
establish the phylogenetic classiﬁcation and nomenclature.
Case-control analysis
Samples were classiﬁed as either controls [including normal,
atypical squamous cells of unknown signiﬁcance (ASCUS),
low-grade intraepithelial lesion (LSIL), or cervical intraepithelial
neoplasia (CIN) 1] or cases [squamous cell carcinoma, adenocarci-
noma, adenosquamous cell carcinoma, or unspeciﬁed invasive
cervical cancer]. Samples from population-based HPV prevalence
studies for which histology and cytology were unavailable were
also classiﬁed as controls (n¼15). Samples reported as CIN2, CIN3,
or high-grade squamous intraepithelial lesion (HSIL) were
excluded from the case-control analysis (n¼15), but were included
in the previously described phylogenetic analysis. Region-speciﬁc
associations between variant (sub)lineage and case-control status
were assessed by 2-sided p-values arising from Fisher's exact test
Table 1
Geographic distribution of 213 HPV33-positive cer-
vical samples
Region/country No.
AFRICA 56
Algeria 2
Guinea 17
Kenya 3
Mali 1
Morocco 3
Nigeria 4
Senegal 13
South Africa 10
Tanzania 1
Uganda 2
ASIA and OCEANIA 87
Bhutan 21
China 6
Fiji 3
India 13
Korea 5
Mongolia 20
Nepal 3
Thailand 8
Vanuatu 1
Vietnam 7
EUROPE 36
Georgia 7
Italy 5
Poland 10
Spain 14
SOUTH AMERICA 34
Argentina 3
Brazil 6
Chile 7
Colombia 5
Paraguay 11
Peru 2
TOTAL 213
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without combining (sub)lineages. Odds ratios (ORs) and 95%
conﬁdence intervals (CIs) were calculated for the A1 sublineage
vs. the combination of all other (sub)lineages. All statistics were
calculated with SAS version 9.3 (SAS Institute, Cary, NC, USA).
Because of the strong regional heterogeneity, regions were never
combined in the statistical analyses.
Results
Sequencing
The entire E6 and E7 genes were sequenced in a total of 213
HPV33-positive cervical samples from 30 countries, including 56
samples from 10 countries in Africa, 87 samples from 10 countries
in Asia/Oceania, 36 samples from 4 countries in Europe, and 34
samples from 6 countries in South America (Table 1).
A total of 36 SNPs were identiﬁed across the E6 and E7 open
reading frames. The observed combinations of these SNPs resulted
in 28 unique sequences, which will be called variants (Table 2). In
E6, there were 24 SNPs, 16 resulting in amino acid changes. In E7,
there were 12 SNPs, 6 resulting in amino acid changes. No SNPs
were observed in the 14 nucleotide region between the E6 and E7
open reading frames. Thus, 5.3% and 4.1% of the nucleotides in E6
and E7, respectively, were subject to variation. The maximum
nucleotide pairwise difference was approximately 2% for both E6
and E7.
Phylogenetic analysis
Twenty-six of the 28 unique variants clustered into three
groups in the phylogenetic tree (Fig. 1A, Table 2) that corre-
sponded to the previously described (sub)lineages A1, A2, and B
(Chen et al., 2011). Nine variants, representing 24 samples (variant
IDs 2–10 in Table 2), were of the same A1 sublineage as the
prototype variant (NCBI accession number M12732, variant ID 1 in
Table 2, n¼88). Seven variants, representing 65 samples (variant
IDs 11–17 in Table 2), corresponded to the previously reported A2
sublineage, and 9 variants, representing 32 samples (variant IDs
19–27 in Table 2), corresponded to the previously reported B
lineage. Two samples (variant ID 18 in Table 2) were similar in
sequence to the variants in the A2 sublineage, but had three
distinct sites of variation that set them apart from the A2
sublineage. Two samples (variant ID 28 in Table 2) were similar
in sequence to, but also showed considerable differences from,
variants in the B lineage (Table 2). Samples from these two
unusual variants were whole-genome sequenced. The comparison
with other HPV33 genomes (Chen et al., 2011) indicated that
variant 18 represents the novel A3 sublineage, and variant 28
represents the novel C lineage.
The tree structure remained unchanged when additional
unique sequence variants from the literature (Table S1) were
added (Fig. 1B). The 3 main clusters corresponding to (sub)lineages
A1, A2, and B remained obvious. Additional support for a true A3
sublineage came from a similar variant reported by Wu et al.
(2009) (EU918766.1) for which the whole genome sequence was
found to differ by 0.8% and 0.6% from publicly available whole
genome sequences of representatives of the A1 and A2 subli-
neages, respectively.
Variants clustering in each of the (sub)lineages A1, A2, A3, B,
and C showed a speciﬁc “core” pattern of SNPs. There were 13 and
3 nucleotide positions in E6 and E7, respectively, that distin-
guished at least one (sub)lineage from another (dark gray back-
ground for nucleotide positions in Table 2). Further, 9 SNPs were
“diagnostic” (i.e., consistently present and unique), for one (sub)
lineage (light gray background for nucleotide bases in Table 2), but
no such diagnostic SNP existed in E6 or E7 for the A1 sublineage. A
minimum combination of 3 nucleotide genotypes in E6 (e.g., 355,
364, and 387) is required for the correct classiﬁcation of a isolate
into one of ﬁve (sub)lineages, based on the current data.
There was an unequal distribution of HPV33 (sub)lineages
across the regions (Fig. 2). Although the A1 and A2 sublineages
were found across all regions, their relative frequency varied. The
B lineage was speciﬁc to Africa. The two isolates in our study that
are of the A3 sublineage are both from Asia/Oceania (China and
Vanuatu), and the two isolates of the C lineage are both from
Africa (Mali and Nigeria).
Case-control analysis
The distribution of HPV33 variant (sub)lineages was compared
between invasive cervical cancer cases (n¼81) and controls
(n¼117) (Table 3). For this analysis, the samples that were
diagnosed as HSIL, CIN2, or CIN3 were removed (n¼15). The
distribution of variant lineages differed signiﬁcantly between
cases and controls in both Africa and Europe. These differences
were driven by an overrepresentation of the A1 sublineage in the
cases from both regions. The relative risks for the A1 sublineage
compared to all non-A1 lineages were 9.4 (95% CI¼1.9–51.4) and
43.2 (95% CI¼4.0–1945) in Africa and Europe, respectively. No
signiﬁcant difference in the risk for the A1 sublineage was
observed in Asian/Oceania (OR¼0.6, 95% CI¼0.1, 2.8). The small
number of controls from South America precluded a similar
analysis.
Removing the cases for which multiple HPV types were
detected did not substantially change the point estimates,
although the conﬁdence intervals did increase due to the loss of
7 cases in Africa (4 were from the A1 sublineage, 2 from the B
lineage, and 1 from the C lineage) and 6 cases in Europe (5 from
the A1 sublineage and 1 from the A2 sublineage; results not
shown). However, despite the reduction in the number of samples,
the results remained signiﬁcant with a p-value of 0.004 for Africa
and o0.001 for Europe.
When the samples classiﬁed as CIN2/3 or HSIL were included
with the cases, the associations became stronger and more precise
for Africa as 6 cases were added to the A1 sublineage, 1 case was
added to the A2 sublineage, and 3 cases were added to the B
lineage (results not shown). There were no samples classiﬁed as
HSIL or CIN2/3 from Europe. The distribution of cases, controls,
and HSIL/CIN2/3 within each region, country, and variant (sub)
lineage are shown in Table S2.
Discussion
The IARC has one of the largest and most diverse collections of
HPV-genotyped cervical specimens in the world and, therefore, is
uniquely situated to study genetic variations found within the
genome of high-risk HPV types and their geographic and ethnic
distribution as well as their association with cervical cancer risk.
Based on 213 HPV33-positive sequenced samples from 30 coun-
tries in Africa, Asia, Oceania, Europe, and South America, we were
able to identify all previously described HPV33 variant (sub)
lineages (i.e., A1, A2 and B) as well as provide additional levels
of phylogenetic stratiﬁcation with the identiﬁcation of an A3
sublineage and a C lineage. This phylogenetic tree structure was
robust even when the analysis was expanded to include additional
sequences from the published literature (Chen et al., 2011;
Khouadri et al., 2006; Garbuglia et al., 2007; Wu et al., 2009).
Our analysis was particularly informative with respect to describ-
ing the variants of HPV33 in Africa and Asia/Oceania because
samples from these areas were better represented here than in
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Table 2
HPV33 variants based on the sequence of the E6 and E7 regions of 213 HPV33-positive cervical samples.
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previous studies. Indeed, the amount of genetic variation in E6 and
E7 captured among our samples (5.3% and 4.1% of nucleotides,
respectively) was higher than in any previous study of HPV33
variants (Chen et al., 2011; Stewart et al., 1996; Godínez et al.,
2013; Khouadri et al., 2006; Bokal et al., 2010; Gagnon et al., 2004;
Garbuglia et al., 2007; Ntova et al., 2012; Raiol et al., 2009; Wu
et al., 2009; Xin et al., 2001).
The distribution of major HPV33 variant lineages around the
world was conﬁrmed to be highly geographically/ethnically
speciﬁc. The A1 sublineage was observed to be distributed
throughout the world, although the relative frequency varied by
region. The A2 sublineage was rarely detected in Africa and South-
America while the B lineage was speciﬁc for Africa. The C lineage
was only found in samples from Africa, and the A3 sublineage was
speciﬁc for Asia/Oceania, as supported by two additional reports
from China (Wu et al., 2009) and Japan [based on E6 only, (Xin
et al., 2001)]. However, the observed rarity of the A3 and C (sub)
lineages and the limited number of samples from the Americas
must be considered when interpreting these results.
While the geographic heterogeneity of the variant sublineages
hampers the possibility to compare their carcinogenic potential
across all regions, by using a multicenter case-control comparison
stratiﬁed by region we were able to identify signiﬁcant associa-
tions between HPV33 variant sublineages and cervical cancer risk.
Our data suggested an overrepresentation of the A1 sublineage
variants in cervical cancer cases in Europe and Africa. Although we
did not observe such an effect in Asia/Oceania, an increased risk of
CIN3 and invasive cervical cancer has been reported for A1
lineages in a study from Japan (Xin et al., 2001).
We did not observe any changes in amino acids at critical
positions related to known biological functions. In E6, there were
no changes in the amino acid sequences that are critical for zinc
binding, TP53 binding (Y54), E6AP binding (I128), nor PDZ binding
(RETAL at positions 145–149). In E7, there were no mutations in
the prototypical LXCXE RB1 binding site at positions 22–26, in the
two CKII phosphorylation sites at serines 31 and 32, nor in the
zinc-binding motif. The lack of mutations in biologically relevant
positions mirrors that which was seen in the analysis of HPV16 E6
variants (Cornet et al., 2012, personal communication).
However, this does not preclude the possibility of signiﬁcant
biological effects caused by changes in amino acids that have not
yet been mapped to a speciﬁc biological or oncogenic function. In
fact, the HPV33 E6 variant containing the combination of I73L,
V83L, K93N, A138V, and silent mutations at F69 and S142, has
been found to be better at degrading P53 and MAGI-3 than the
prototype HPV33 E6 (Ainsworth et al., 2008). Similarly, there is the
possibility of linked mutations in other regions of the HPV33
genome that have a role in the oncogenic potential of the virus.
Therefore, differences in HPV33-associated cervical cancer rates by
population might be explained by genetic heterogeneity within
the HPV33 variant sublineages around the world. Alternatively or
additionally, host genetic factors, which differ by population, could
have a role in the association between a particular HPV33 variant
and cervical cancer development, as has been suggested for HPV16
(Zehbe et al., 2001).
To facilitate epidemiological studies comparing the clinical beha-
vior of HPV33 genetic variants and their eventual pooling for sample
size requirements, we highlight a practical classiﬁcation of all HPV33
Fig. 1. Phylogenetic trees of the HPV33 E6 and E7 variants in the present study only (A) or with additional variants published in the literature (B). The numbers at the end of
the branches correspond to variants listed in Table 2 and Table S1. The prototype sequence is variant 1 in the A1 sublineage.
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variant sublineages based upon a selection of 16 discriminatory
nucleotide positions in E6 and E7, that can each distinguish at least
one (sub)lineage described above from another. Nevertheless, there is
redundancy in this classiﬁcation, so that a minimum of 3 nucleotide
genotypes in E6 (e.g., positions 355, 364, and 387) is required for
correct lineage classiﬁcation. Although there is a small number of
diagnostic SNPs that are speciﬁc for a given sublineage, none exist for
the most common A1 sublineage.
Of note, the use of these SNPs for HPV33 sublineage classiﬁca-
tion ﬁts with all other HPV33 sequences published in the literature
(Table S1) and is consistent with previous lineage deﬁnitions
based on complete HPV33 genome sequencing (Chen et al.,
2011). Thus, while whole genome sequencing remains the gold
standard for deﬁning HPV phylogeny, this simple classiﬁcation
based on E6 and E7 may be useful in situations where sample
quality, quantity, or lack of access to appropriate technical plat-
forms is an obstacle to achieving a complete sequence.
The major limitation of the current study was the limited
sample sizes particularly for HPV33-positive cases in Africa and
Asia/Oceania and HPV33-positive controls in South America. The
very high ORs that we report should, therefore, be interpreted
with caution because of the very broad CIs and the possibility that
there is heterogeneity between the countries grouped together by
region given that the distribution of cases and controls was not
balanced by country (Table S2). Nevertheless, the reliance on 20
years of IARC studies on HPV from around the world meant that
the number of HPV33-positive cases and controls in the current
study was by far the largest studied to date.
In conclusion, we provide an updated classiﬁcation of HPV33
phylogeny for use in epidemiological studies and suggest that
HPV33 variant (sub)lineages may be associated with different risks
of cervical cancer. Although our results need to be conﬁrmed in a
large series of cases and controls drawn from the same population,
the current study provides information on the genetic basis of
differences in the carcinogenicity of HPV33 variant lineages and
may help us unravel important biological and/or immunological
interactions between the virus and the host that could lead to better
tools to control HPV infection and its malignant consequences.
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